Author: Gupta, Tania; Gupta, Shishir K
Title: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses Cord-id: npc9qdex Document date: 2020_6_18
ID: npc9qdex
Snippet: The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Furthe
Document: The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This not only decreases the cost of a vaccine and make it affordable, but also reduces the quantity of the antigen used. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging SARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.
Search related documents:
Co phrase search for related documents- access gain and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
- access gain and adjuvant activity: 1
- access gain and liver lung: 1
- acquired immunodeficiency and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
- acquired immunodeficiency and acute respiratory distress syndrome: 1, 2, 3, 4
- acquired immunodeficiency and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acquired immunodeficiency and adaptive innate: 1, 2
- acquired immunodeficiency and adjuvant system: 1
- acquired immunodeficiency and local inflammation: 1
- acquired immunodeficiency syndrome and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- acquired immunodeficiency syndrome and acute respiratory distress syndrome: 1, 2, 3
- acquired immunodeficiency syndrome and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
- acquired immunodeficiency syndrome and adjuvant system: 1
- acquired immunodeficiency syndrome and local inflammation: 1
Co phrase search for related documents, hyperlinks ordered by date